Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Muramyl dipeptide induces NOD2-dependent Ly6C(high) monocyte recruitment to the lungs and protects against influenza virus infection.

Coulombe F, Fiola S, Akira S, Cormier Y, Gosselin J.

PLoS One. 2012;7(5):e36734. doi: 10.1371/journal.pone.0036734. Epub 2012 May 9.

2.

Nod2 and Rip2 contribute to innate immune responses in mouse neutrophils.

Jeong YJ, Kang MJ, Lee SJ, Kim CH, Kim JC, Kim TH, Kim DJ, Kim D, Núñez G, Park JH.

Immunology. 2014 Oct;143(2):269-76. doi: 10.1111/imm.12307.

3.

Contribution of Regulatory T Cells in Nucleotide-Binding Oligomerization Domain 2 Response to Influenza Virus Infection.

Egarnes B, Gosselin J.

Front Immunol. 2018 Jan 31;9:132. doi: 10.3389/fimmu.2018.00132. eCollection 2018.

4.
5.

Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide.

Coulombe F, Divangahi M, Veyrier F, de Léséleuc L, Gleason JL, Yang Y, Kelliher MA, Pandey AK, Sassetti CM, Reed MB, Behr MA.

J Exp Med. 2009 Aug 3;206(8):1709-16. doi: 10.1084/jem.20081779. Epub 2009 Jul 6.

6.

Bacterial Muramyl Dipeptide (MDP) Restricts Human Cytomegalovirus Replication via an IFN-β-Dependent Pathway.

Kapoor A, Fan YH, Arav-Boger R.

Sci Rep. 2016 Feb 2;6:20295. doi: 10.1038/srep20295.

7.

Clathrin- and dynamin-dependent endocytic pathway regulates muramyl dipeptide internalization and NOD2 activation.

Marina-García N, Franchi L, Kim YG, Hu Y, Smith DE, Boons GJ, Núñez G.

J Immunol. 2009 Apr 1;182(7):4321-7. doi: 10.4049/jimmunol.0802197.

8.

Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.

Yang S, Takahashi N, Yamashita T, Sato N, Takahashi M, Mogi M, Uematsu T, Kobayashi Y, Nakamichi Y, Takeda K, Akira S, Takada H, Udagawa N, Furusawa K.

J Immunol. 2005 Aug 1;175(3):1956-64.

9.

Triggering of NOD2 Receptor Converts Inflammatory Ly6Chigh into Ly6Clow Monocytes with Patrolling Properties.

Lessard AJ, LeBel M, Egarnes B, Préfontaine P, Thériault P, Droit A, Brunet A, Rivest S, Gosselin J.

Cell Rep. 2017 Aug 22;20(8):1830-1843. doi: 10.1016/j.celrep.2017.08.009.

10.
11.

The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype.

Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G.

Genes Immun. 2008 Apr;9(3):274-8. doi: 10.1038/gene.2008.9. Epub 2008 Mar 13.

PMID:
18340358
12.

NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2.

Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher MA.

J Biol Chem. 2007 Dec 14;282(50):36223-9. Epub 2007 Oct 18.

13.

Freund's adjuvant, NOD2 and mycobacteria.

Behr MA, Divangahi M.

Curr Opin Microbiol. 2015 Feb;23:126-32. doi: 10.1016/j.mib.2014.11.015. Epub 2014 Dec 5. Review.

PMID:
25483349
14.

NOD2 ligation subverts IFN-alpha production by liver plasmacytoid dendritic cells and inhibits their T cell allostimulatory activity via B7-H1 up-regulation.

Castellaneta A, Sumpter TL, Chen L, Tokita D, Thomson AW.

J Immunol. 2009 Dec 1;183(11):6922-32. doi: 10.4049/jimmunol.0900582. Epub 2009 Nov 4.

15.

NOD2: a potential target for regulating liver injury.

Body-Malapel M, Dharancy S, Berrebi D, Louvet A, Hugot JP, Philpott DJ, Giovannini M, Chareyre F, Pages G, Gantier E, Girardin SE, Garcia I, Hudault S, Conti F, Sansonetti PJ, Chamaillard M, Desreumaux P, Dubuquoy L, Mathurin P.

Lab Invest. 2008 Mar;88(3):318-27. doi: 10.1038/labinvest.3700716. Epub 2008 Jan 28.

16.

A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-β synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growth.

Fujimura T, Yamasaki K, Hidaka T, Ito Y, Aiba S.

J Dermatol Sci. 2011 May;62(2):107-15. doi: 10.1016/j.jdermsci.2011.02.002. Epub 2011 Feb 22.

PMID:
21411292
17.

NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction.

Yang Z, Fuss IJ, Watanabe T, Asano N, Davey MP, Rosenbaum JT, Strober W, Kitani A.

Gastroenterology. 2007 Nov;133(5):1510-21. Epub 2007 Jul 25.

18.

MDP-Induced selective tolerance to TLR4 ligands: impairment in NOD2 mutant Crohn's disease patients.

Cantó E, Moga E, Ricart E, Garcia-Bosch O, Garcia-Planella E, Juarez C, Vidal S.

Inflamm Bowel Dis. 2009 Nov;15(11):1686-96. doi: 10.1002/ibd.21013.

PMID:
19572373
19.

NOD2 dependent neutrophil recruitment is required for early protective immune responses against infectious Litomosoides sigmodontis L3 larvae.

Ajendra J, Specht S, Ziewer S, Schiefer A, Pfarr K, Parčina M, Kufer TA, Hoerauf A, Hübner MP.

Sci Rep. 2016 Dec 22;6:39648. doi: 10.1038/srep39648.

20.

NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes.

Beynon V, Cotofana S, Brand S, Lohse P, Mair A, Wagner S, Mussack T, Ochsenkühn T, Folwaczny M, Folwaczny C, Glas J, Török HP.

Inflamm Bowel Dis. 2008 Aug;14(8):1033-40. doi: 10.1002/ibd.20441.

PMID:
18383179

Supplemental Content

Support Center